Table 4.
Best response | AML | ALL | MDS | CML-BC | Total |
---|---|---|---|---|---|
(number of patients) | |||||
Complete remission (CR) | 1 | 0 | 0 | 0 | 1 |
Stable disease (SD) | 12 | 1 | 4 | 1 | 18 |
Progressive disease (PD) | 13 | 1 | 1 | 1 | 16 |
Not assessed / Not evaluable‡ | 2 | 0 | 1 | 0 | 3 |
Study participation discontinued prior to disease assessment timepoint (1 withdrew for personal reasons; 2 discontinued study treatment for unrelated adverse events)